Announcement on the Resignation of Core Technical Personnel
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
Kexing Biopharm Co., Ltd. announced the resignation of core technical personnel, specifically Mr. Li Huiming, due to personal reasons. Mr. Li's departure will not adversely affect the company's research and development capabilities or core competitiveness. The company confirmed that all intellectual property developed during Mr. Li's tenure remains owned by the company and its subsidiaries.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Kexing Biopharm Co., Ltd. on 6ix
Earlier from Kexing Biopharm
- Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
- Announcement on the Achievements of Vesting Conditions in the 2nd Vesting Period of the 2024 Restricted Stock Incentive Plan
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of GB10 for Injection
- Announcement on Resolutions of the 2025 Annual General Meeting
Later from Kexing Biopharm
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Granting of Restricted Stocks to Incentive Objects
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Vesting Results for the 2nd Vesting Period under the 2024 Restricted Stock Incentive Plan and the Listing of Shares
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Change of Sponsor Representative for Continuous Supervision
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
Follow Kexing Biopharm into a list and get an email when it puts out news.
Follow Kexing Biopharm